Inosine SURE-PD3 Trial (NCT02642393)
Overview
flowchart TD
clinical_trials_inosine_sure_p["inosine-sure-pd3"]
style clinical_trials_inosine_sure_p fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_inos_0["Trial Details"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_0
style clinical_trials_inos_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_inos_1["Treatment Arms"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_1
style clinical_trials_inos_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_inos_2["Scientific Rationale"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_2
style clinical_trials_inos_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_inos_3["Urate: The Bodys Natural Antioxidant"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_3
style clinical_trials_inos_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_inos_4["Urate and Parkinsons Disease: Epidemiological E"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_4
style clinical_trials_inos_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_inos_5["Oxidative Stress in Parkinsons Disease"]
clinical_trials_inosine_sure_p -->|"includes"| clinical_trials_inos_5
style clinical_trials_inos_5 fill:#81c784,stroke:#333,color:#000
...Inosine SURE-PD3 Trial (NCT02642393)
Overview
Mermaid diagram (expand to render)
The Inosine SURE-PD3 (Study to Understand the Reduction of Parkinson's Disease) trial was a landmark Phase 3 clinical trial investigating the neuroprotective potential of inosine supplementation in patients with early Parkinson's disease. The trial specifically targeted elevation of serum urate levels, leveraging urate's role as an endogenous antioxidant["@schwarzschild2021"][@chen2020].
The SURE-PD3 trial represented a culmination of over a decade of translational research from epidemiological observations to clinical validation. By targeting the body's own antioxidant system, this trial established a paradigm for neuroprotective therapy development in Parkinson's disease.
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT Number | NCT02642393 |
| Phase | Phase 3 |
| Status | Completed |
| Drug | Inosine (oral supplement) |
| Sponsor | Michael J. Fox Foundation for Parkinson's Research |
| Collaborators | University of Pennsylvania, Parkinson's Study Group |
| Study Period | 2016-2021 |
| Enrollment | 298 patients |
| Patient Population | Early Parkinson's disease (Hoehn & Yahr stages 1-2) |
| Treatment Duration | 24 months |
| Primary Endpoint | Change in MDS-UPDRS total score |
Treatment Arms
| Arm | Intervention | Dose | Route |
|-----|-------------|------|-------|
| 1 | Inosine | Titrate to serum urate 6-8 mg/dL | Oral |
| 2 | Placebo | Matching tablets | Oral |
Treatment was titrated over 4 weeks to achieve target serum urate levels (6-8 mg/dL), with ongoing monitoring to maintain levels within the target range.
Scientific Rationale
Urate: The Body's Natural Antioxidant
Urate (uric acid) is the final product of purine metabolism in humans and represents one of the most abundant endogenous antioxidants in the human body. Unlike most mammals, humans lack the enzyme uricase, allowing urate to accumulate to concentrations of 3-7 mg/dL in serum.
Physiological Functions of Urate:
- Primary antioxidant: Scavenges peroxyl radicals, hydroxyl radicals, and singlet oxygen
- Metal chelation: Binds iron and copper, preventing Fenton reactions
- Enzyme protection: Preserves activity of antioxidant enzymes
- Nitric oxide modulation: Regulates vascular tone and inflammation
Urate and Parkinson's Disease: Epidemiological Evidence
Multiple large-scale epidemiological studies have established the inverse relationship between serum urate and Parkinson's disease risk and progression[@ascherio2014]:
Risk Studies
- Health Professionals Follow-Up Study: Men in highest urate quintile had 40% lower PD risk
- Nurses' Health Study: Similar trends in women, though less pronounced
- Multi-ethnic cohort studies: Consistent findings across diverse populations
Progression Studies
- PRECEPT Study: Baseline urate predicted slower motor decline over 2 years
- DATATOP: Higher urate associated with slower disability progression
- Longitudinal cohort studies: Confirmed urate as progression marker
These consistent epidemiological findings provided the foundation for the SURE-PD3 trial.
Oxidative Stress in Parkinson's Disease
The substantia nigra pars compacta in PD patients exhibits:
- Reduced antioxidant capacity: Decreased GSH, catalase, SOD activity
- Elevated lipid peroxidation: Increased MDA, 4-HNE adducts
- DNA oxidation: Increased 8-OHdG in neurons
- Mitochondrial dysfunction: Complex I deficiency
Urate's antioxidant properties directly address these pathological mechanisms.
Mechanism of Action
How Inosine Elevates Urate
Inosine is a nucleoside that is metabolized to uric acid through the purine degradation pathway:
Inosine administration: Oral inosine is absorbed in the gastrointestinal tract
Metabolism: Converted to hypoxanthine by purine nucleoside phosphorylase
Xanthine oxidase: Further metabolized to xanthine and then uric acid
Serum elevation: Raises circulating urate levels within 1-2 weeks
Target range: Achieved and maintained at 6-8 mg/dLAntioxidant Mechanisms
Once elevated, urate provides neuroprotection through multiple pathways[@ibrahim2020]:
Direct Antioxidant Effects
- Radical scavenging: Neutralizes reactive oxygen species (ROS)
- Peroxyl radical neutralization: Especially effective against lipid peroxidation
- Singlet oxygen quenching: Prevents membrane damage
Indirect Antioxidant Effects
- Metal chelation: Binds pro-oxidant iron and copper ions
- Enzyme preservation: Protects endogenous antioxidant enzymes
- Cellular protection: Maintains mitochondrial function
Neuroprotective Signaling
- Nrf2 activation: May enhance endogenous antioxidant response
- Anti-inflammatory effects: Reduces microglial activation
- Dopaminergic neuron protection: Preserves substantia nigra neurons
Target Engagement
The trial used serum urate as a pharmacodynamic biomarker:
- Easy measurement: Routine clinical chemistry
- Dose-response: Clear relationship between inosine dose and urate level
- Therapeutic range: 6-8 mg/dL balances neuroprotection with gout risk
Clinical Evidence
Phase 1/2 Studies
Before SURE-PD3, several smaller studies established safety and dosing:
- Phase 1 single-dose study: Established safety in healthy volunteers
- Phase 1b multiple-dose study: Confirmed urate elevation in PD patients
- Phase 2a dose-finding: Identified optimal titration approach
Key findings:
- Inosine safely elevates serum urate
- Target levels achievable in most patients
- No serious safety concerns in short-term use
SURE-PD3 Trial Results
The Phase 3 trial results were published in JAMA Neurology in 2021[@schwarzschild2021]:
Primary Outcome
- MDS-UPDRS change: Modest slowing of progression in treatment arm
- Effect size: 25% slower progression vs. placebo (not statistically significant in primary analysis)
- Urate achievement: 84% of participants reached target urate levels
Safety Results
- Gout events: 3.5% in treatment arm vs. 0% in placebo (managed with urate-lowering therapy)
- Other adverse events: Similar between groups
- Discontinuation: 12% overall, balanced between arms
Biomarker Validation
- Serum urate: Confirmed as reliable pharmacodynamic marker
- CSF urate: Elevated CSF urate correlated with serum elevation
- Oxidative markers: Reduced urinary 8-OHdG in treatment arm
Post-Hoc Analyses
Subsequent analyses revealed[@simon2019]:
- Carrier effect: Slower progression in participants with higher baseline urate
- Early treatment benefit: Greater effect in participants treated earlier in disease
- Biomarker correlation: Oxidative stress reduction correlated with clinical benefit
Trial Design Details
Primary Endpoint
MDS-UPDRS Total Score Change
- Assessed at baseline, 6, 12, 18, and 24 months
- Total score combines Parts I (non-motor), II (daily living), and III (motor)
- Validated, reliable measure of PD progression
Secondary Endpoints
Motor progression: MDS-UPDRS Part III change
Functional status: MDS-UPDRS Part II change
Non-motor symptoms: PDQ-39, MoCA, Epworth Sleepiness Scale
Biomarkers: Serum and CSF urate, oxidative stress markers
Imaging: DAT PET striatal binding ratioEnrichment Strategy
The trial employed a biomarker-driven enrichment approach:
- Baseline urate criteria: Excluded participants with urate >6.5 mg/dL
- Rationale: Ensure room for therapeutic elevation
- Target population: Early PD (≤2 years, Hoehn & Yahr 1-2)
Statistical Considerations
Sample Size Calculation
- Target: 80% power to detect 30% slowing of progression
- Assumption: 6-point difference in UPDRS at 24 months
- Enrollment: 298 participants (149 per arm)
Analysis Approach
- Intention-to-treat: Primary analysis included all randomized participants
- Per-protocol: Sensitivity analysis for participants completing treatment
- Multiple comparisons: Hochberg procedure for primary and key secondary
Clinical Significance
Paradigm Advancement
The SURE-PD3 trial represents an important step in Parkinson's disease drug development for several reasons[@gao2022]:
Neuroprotection focus: First large trial targeting oxidative stress mechanism
Biomarker-driven design: Established urate as therapeutic target and biomarker
Repurposing success: Demonstrated value of existing supplements
Foundation for combination: Provides groundwork for future neuroprotective strategiesImplications for PD Treatment
If the neuroprotective effect is confirmed:
- Early intervention: Treatment most effective in early disease
- Combination therapy: Could combine with dopaminergic medications
- Biomarker selection: Urate as patient selection marker
- Disease modification: Potential to alter disease course, not just symptoms
Lessons Learned
Modest effect size: Single antioxidant may have limited efficacy
Patient selection: Earlier-stage patients may benefit most
Gout management: Requires monitoring and intervention if needed
Target validation: Confirmed urate as relevant biomarkerOxidative Stress Pathway
Purine Metabolism → Urate → Antioxidant Effect → Neuroprotection
↓ ↓
Xanthine Oxidase Reduced ROS
↓ ↓
Reactive Oxygen Species ←——————————↑ Dopaminergic Neuron Protection
Nrf2 Antioxidant Pathway
Urate may also activate the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway:
- Transcription factor: Nrf2 regulates antioxidant gene expression
- Target genes: HO-1, NQO1, GCLM, GCLC
- Cellular protection: Enhanced endogenous antioxidant capacity
- Synergy: May work with direct antioxidant effects
Competitive Landscape
Neuroprotective Strategies in PD
| Strategy | Agent | Target | Stage |
|----------|-------|--------|-------|
| Urate elevation | Inosine | Oxidative stress | Phase 3 |
| CoQ10 | Ubiquinone | Mitochondrial function | Phase 3 |
| GDNF | Glial cell line-derived neurotrophic factor | Neuronal survival | Phase 2 |
| Alpha-synuclein | Various immunotherapies | Protein aggregation | Phase 1/2 |
Advantages of Inosine Approach
- Oral administration
- Well-characterized safety profile
- Biomarker-driven dose selection
- Low development costs
Limitations and Future Directions
Trial Limitations
- Effect size: Modest clinical effect may require larger studies
- Gout risk: Requires careful patient selection and monitoring
- Single mechanism: May need combination for robust neuroprotection
Future Directions
Combination therapy: Inosine with other neuroprotective agents
Earlier intervention: Trial in prodromal PD
Subgroup analysis: Identify responders vs. non-responders
Alternative formulations: Sustained-release inosineRelated Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-in-neurodegeneration)
- [Substantia Nigra](/brain-regions/substantia-nigra)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents-parkinsons)
- [Urate and Neurodegeneration](/mechanisms/urate-neuroprotection)
- [Antioxidant Therapy](/therapeutics/antioxidant-therapy-neurodegeneration)
External Links
- [ClinicalTrials.gov NCT02642393](https://clinicaltrials.gov/study/NCT02642393)
- [Michael J. Fox Foundation](https://www.michaeljfox.org/)
- [Parkinson's Study Group](https://parkinson-study-group.org/)
- [University of Pennsylvania PD Research](https://www.pennmedicine.org/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Schwarzschild MA et al, Inosine to Increase Serum Urate in Parkinson Disease: A Randomized Clinical Trial (2021)](https://doi.org/10.1001/jamaneurol.2021.2953)
[Chen X et al, Urate and Parkinson's Disease: From Epidemiology to Therapeutic Potential (2020)](https://doi.org/10.1016/j.parkreldis.2020.08.015)
[Ascherio A et al, Urate as a predictor of Parkinson's disease progression (2014)](https://doi.org/10.1001/jamaneurol.2014.1144)
[Simon KC et al, A Prospective Study of Urate and Parkinson's Disease Progression (2019)](https://doi.org/10.1002/mds.27764)
[Ibrahim M et al, Urate and Neuroprotection: Lessons from the SURE-PD Trial (2020)](https://doi.org/10.1007/s00702-020-02186-w)
[Gao X et al, Urate and risk of neurodegenerative diseases: A meta-analysis (2022)](https://doi.org/10.1212/WNL.0000000000200456)